Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.64 |
| ▸ | CASP7 | P55210 | 11/20 | 0.64 |
| ▸ | CASP1 | P29466 | 7/20 | 0.64 |
| ▸ | CASP9 | P55211 | 5/20 | 0.64 |
| ▸ | CASP4 | P49662 | 3/20 | 0.52 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
| ▸ | CASP5 | P51878 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038936 | 0.96 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2043662 | 0.93 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL4461379 | 0.92 | CASP3 (0.64) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2038060 | 0.91 | CASP3 (0.63) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2033191 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL713780 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL4952116 | 0.88 | CASP3 (0.60) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2039051 | 0.87 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL7168373 | 0.86 | CASP1 (0.58) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL2040978 | 0.86 | CASP3 (0.57) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220017944-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| EP-3401406-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GmbH (DE) | 2018-11-14 | — | — | EP | disclosed |
| EP-2976424-B1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2018-10-03 | — | — | EP | disclosed |
| EP-2761020-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-20160348151-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160281132-A1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160281133-A1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| EP-2761000-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20150275268-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20140227688-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227687-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.